Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Chuan-Chia Chang, Nian-Sheng Tzeng, Chin-Bin Yeh, Terry B. J. Kuo, San-Yuan Huang & Hsin-An Chang. (2018) Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative–hypnotics on heart rate variability: Implications for cardiovascular risk. The World Journal of Biological Psychiatry 19:5, pages 368-378.
Read now
Read now
Massimiliano Buoli, Silvia Grassi, Marta Serati & A. Carlo Altamura. (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy 18:13, pages 1373-1379.
Read now
Read now
Stefano Paolucci. (2017) Advances in antidepressants for treating post-stroke depression. Expert Opinion on Pharmacotherapy 18:10, pages 1011-1017.
Read now
Read now
Tomas Richter, Stefan Alusik, Zoltan Paluch, Ilona Burianova, Anatolij Cybulja & Lenka Sadilkova. (2015) Suppressive effect of citalopram on plasma concentrations of thromboxane B2. Scandinavian Journal of Clinical and Laboratory Investigation 75:7, pages 615-620.
Read now
Read now
Articles from other publishers (31)
Christopher A. Crawford, Michelle K. Williams, Aubrey L. Shell, Krysha L. MacDonald, Robert V. Considine, Wei Wu, Kevin L. Rand & Jesse C. Stewart. (2023) Effect of modernized collaborative care for depression on brain-derived neurotrophic factor (BDNF) and depressive symptom clusters: Data from the eIMPACT trial. Psychiatry Research 330, pages 115581.
Crossref
Crossref
P. Zuccarello, G. Carnazza, A. Giorlandino, S. Cosentino, V. Arcifa & N. Barbera. (2023) Lethal vortioxetine poisoning? A forensic investigation. Legal Medicine 65, pages 102314.
Crossref
Crossref
Hanan H. Ahmed, Reham M. Essam, Muhammed F. El-Yamany, Kawkab A. Ahmed & Ayman E. El-Sahar. (2023) Unleashing lactoferrin's antidepressant potential through the PI3K/Akt/mTOR pathway in chronic restraint stress rats. Food & Function 14:20, pages 9265-9278.
Crossref
Crossref
Omar Salem Gammoh & Rasha Bashatwah. (2023) Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory. Electronic Journal of General Medicine 20:5, pages em513.
Crossref
Crossref
Jesse C. Stewart, Jay S. Patel, Brittanny M. Polanka, Sujuan Gao, John I. Nurnberger, Krysha L. MacDonald, Samir K. Gupta, Robert V. Considine, Richard J. Kovacs, Elizabeth A. Vrany, Jessica Berntson, Loretta Hsueh, Aubrey L. Shell, Bruce L. Rollman & Christopher M. Callahan. (2023) Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trial. Brain, Behavior, and Immunity 112, pages 18-28.
Crossref
Crossref
Ivana Bojanić, Ottar Bjerkeset, Lana J. Williams, Michael Berk, Johan Håkon Bjørngaard, Erik R. Sund & Hege Sletvold. (2023) Risk of antidepressant initiation among users of cardiovascular agents and metformin.. Pharmacology Research & Perspectives 11:2.
Crossref
Crossref
Sophia KeinsJessica R. Abramson, Akashleena Mallick, Juan Pablo CastelloAxana Rodriguez-Torres, Dominique Popescu, Danielle Hoffman, Christina Kourkoulis, M. Edip Gurol, Steven M. Greenberg, Christopher D. Anderson, Anand Viswanathan, Jonathan Rosand & Alessandro Biffi. (2023) Association of Depression Onset and Treatment With Blood Pressure Control After Intracerebral Hemorrhage. Stroke 54:1, pages 105-112.
Crossref
Crossref
Maša Čater & Sabine M. Hölter. (2022) A Pathophysiological Intersection of Diabetes and Alzheimer’s Disease. International Journal of Molecular Sciences 23:19, pages 11562.
Crossref
Crossref
Ivana Bojanić, Ottar Bjerkeset, Lana J. Williams, Michael Berk, Erik R. Sund & Hege Sletvold. (2022) Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway. Drugs - Real World Outcomes 9:3, pages 503-516.
Crossref
Crossref
Narayan Chaurasiya, Francisco Leon, Ilias Muhammad & Babu Tekwani. (2022) Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma. Molecules 27:13, pages 4297.
Crossref
Crossref
Hung-Tsung Hsiao, Jeffrey Chi-Fei Wang & Sheng-Nan Wu. (2022) Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant. Biomedicines 10:6, pages 1318.
Crossref
Crossref
Kai G. Kahl, Britta Stapel & Christoph U. Correll. (2022) Psychological and Psychopharmacological Interventions in Psychocardiology. Frontiers in Psychiatry 13.
Crossref
Crossref
PrasadRao Gundugurti, Ranjan Bhattacharyya & Amulya Koneru. (2022) Management of psychiatric disorders in patients with cardiovascular diseases. Indian Journal of Psychiatry 64:8, pages 355.
Crossref
Crossref
Shengwei Wu, Yufang Zhou, Zhengzheng Xuan, Linghui Xiong, Xinyu Ge, Junrong Ye, Yun Liu, Lexin Yuan, Yan Xu, Guoan Ding, Aixiang Xiao, Jianxiong Guo & Lin Yu. (2021) Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study. Scientific Reports 11:1.
Crossref
Crossref
Shivang Joshi, Stewart J. Tepper, Sylvia Lucas, Soeren Rasmussen & Rob Nelson. (2021) A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management. Headache: The Journal of Head and Face Pain 61:6, pages 838-853.
Crossref
Crossref
Pierre BaumannGilles BertschyFritz Ramseier & Rico Nil. (2021) Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression. Therapeutic Drug Monitoring 43:3, pages 436-442.
Crossref
Crossref
Hugo Martin, Sébastien Bullich, Bruno P. Guiard & Xavier Fioramonti. (2021) The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders. Journal of Neuroendocrinology 33:4.
Crossref
Crossref
Vimal M. Aga, Mujeeb U. Shad, Hongru Zhu & Carl Salzman. 2020. Handbook of Mental Health and Aging. Handbook of Mental Health and Aging
315
399
.
Evangelia Mareti, Christina Ampatzi, Stavroula A. Paschou, Evangelia Voziki & Dimitrios G. Goulis. (2019) Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?. Current Vascular Pharmacology 17:6, pages 573-578.
Crossref
Crossref
Kai G. Kahl. (2018) Direct and indirect effects of psychopharmacological treatment on the cardiovascular system. Hormone Molecular Biology and Clinical Investigation 36:1.
Crossref
Crossref
Mashhood Ahmed Sheikh. (2018) Leisure time physical activity and incident use of prescription tranquilizers: A longitudinal population-based study. Journal of Affective Disorders 238, pages 327-335.
Crossref
Crossref
Alun C Jackson, David A Barton & Barbara M Murphy. (2018) Major psychiatric disorders and the aetiology and progression of coronary heart disease. British Journal of Cardiac Nursing 13:9, pages 446-454.
Crossref
Crossref
Ronit Almog, Shemy Carasso, Idit Lavi & Offer Amir. (2018) The risk for a first acute coronary syndrome in patients treated with different types of antidepressants: A population based nested case-control study. International Journal of Cardiology 267, pages 28-34.
Crossref
Crossref
Hiroya Mizutani, Fukumitsu Sakakibara, Masahito Komuro & Eiji Sasaki. (2018) TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence. Journal of Pharmacology and Experimental Therapeutics 366:2, pages 322-331.
Crossref
Crossref
Luiz Fernando Veríssimo, Vinicius Lucca Volpini, Viviane Batista Estrada, Natália Kimie Matsubara, Marcus Vinicius Gomes, Leonardo Barbosa Moraes Resstel, Fernando Morgan Aguiar Correa & Gislaine Garcia Pelosi. (2018) Treatment with escitalopram modulates cardiovascular function in rats. European Journal of Pharmacology 824, pages 120-127.
Crossref
Crossref
Sylva Racková. (2018) Agomelatine for treating depression in somatic diseases. Praktické lékárenství 14:1, pages 12-15.
Crossref
Crossref
Sheng-Min WangChangsu HanWon-Myoung BahkSoo-Jung LeeAshwin A. PatkarPrakash S. MasandChi-Un Pae. (2018) Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal 54:2, pages 101.
Crossref
Crossref
Kai G. Kahl, Mechthild Westhoff-Bleck & Tillmann H.C. Krüger. (2017) Effects of psychopharmacological treatment with antidepressants on the vascular system. Vascular Pharmacology 96-98, pages 11-18.
Crossref
Crossref
Ta-Chuan Yeh, Lien-Cheng Kao, Nian-Sheng Tzeng, Terry B.J. Kuo, San-Yuan Huang, Chuan-Chia Chang & Hsin-An Chang. (2016) Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA). Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 60-67.
Crossref
Crossref
Cecilio Álamo, Francisco López-Muñoz & Pilar García-García. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
445
463
.
Christoph U. Correll, Johan Detraux, Jan De Lepeleire & Marc De Hert. (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14:2, pages 119-136.
Crossref
Crossref